OPKO Health Inc (OPKO) discovers, develops, and commercializes therapeutics and diagnostic products. The products include molecular diagnostics tests, point-of-care tests, and proprietary pharmaceuticals and vaccines, among others. The company’s proprietary technologies include Carboxyl Terminal Peptide (CTP) technology, reversible PEGylation technology, and AntagoNAT technology. The company, through its BioReference laboratory, offers services to hospitals, physicians' offices, clinics, employers, and governmental units in Maryland, New York, Pennsylvania, New Jersey, Delaware, Washington, Massachusetts, Florida, California, Texas, and Illinois.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

OPKO Health is actively engaged in research and development initiatives focusing on immuno-oncology, infectious disease programs, and the development of proprietary pharmaceutical products such as Rayaldee and NGENLA. The company is also advancing multispecific antibodies for viral infectious diseases under a contract with the Biomedical Advanced Research and Development Authority (BARDA). The BARDA contract supports the development of a tetravalent bispecific antibody targeting the SARS-CoV-2 spike protein and a multispecific influenza antibody candidate. The company's research and development activities are primarily conducted in facilities located in Weston, Massachusetts; Waterford, Ireland; Kiryat Gat, Israel; and Barcelona, Spain. These units are responsible for managing the company's R&D activities, including clinical and non-clinical activities, lab services, and manufacturing development costs. In FY2025, the company spent US$124 million on R&D, which, as a percentage of revenue, stood at 20.4% and grew 17.8% YoY. Some of its pipeline drugs in Phase III include NGENLA for Other Pediatric Indications. It also has pipeline drugs through its subsidiary, such as MDX2201, for the treatment of infectious mono and EBV-related cancers; MDX2001 for solid tumors; MDX2004 for Solid Tumors, Blood Cancers, and Immune Impairment; MDX2003 for the treatment of B-Cell Leukemia and autoimmunity; and MDX2301 for COVID-19 treatment.